{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:13:47Z","timestamp":1794554027160,"version":"4.9.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Some studies have found that probiotics have the potential to treat PD, and earthworm protein is a traditional Chinese medicine used for the treatment of PD. The purpose of this study was to evaluate the safety and efficacy of <jats:italic>Bacteroides fragilis<\/jats:italic> 839 (<jats:italic>BF<\/jats:italic>839)\u2009+\u2009earthworm protein supplement as an adjunctive therapy for PD and to observe changes in the gut microbiota.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty-six patients with PD were recruited for a 12-week 1:1 randomized, double-blind, placebo-controlled clinical trial to evaluate changes in motor and some non-motor symptom scores and detect metagenomic changes in the gut microbiota.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From baseline to 12\u2009weeks, compared with placebo, the trial group showed significant reductions in the United Parkinson\u2019s Disease Rate Scale (UPDRS) total score (\u22127.74\u2009\u00b1\u20095.92 vs. \u20131.83\u2009\u00b1\u20094.14, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), UPDRS part I (\u22120.72\u2009\u00b1\u20090.81 vs. \u20130.20\u2009\u00b1\u20090.72, <jats:italic>p<\/jats:italic>\u2009=\u20090.026), UPDRS part II (\u22122.50\u2009\u00b1\u20092.24 vs. \u20130.22\u2009\u00b1\u20091.98, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), UPDRS part III (\u22123.43\u2009\u00b1\u20093.42 vs. \u20131.33\u2009\u00b1\u20092.65, <jats:italic>p<\/jats:italic>\u2009=\u20090.024), and UPDRS part IV (\u22121.13\u2009\u00b1\u20091.19 vs. \u20130.15\u2009\u00b1\u20090.57, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Significant reductions in the Hamilton Depression Scale-24 score (\u22123.91\u2009\u00b1\u20093.99 vs. +1.15\u2009\u00b1\u20093.42, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), Self-Rating Anxiety Scale scores (\u22127.04\u2009\u00b1\u20095.71 vs. \u20131.23\u2009\u00b1\u20092.34, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), and Constipation scoring system scores (\u22128.59\u2009\u00b1\u20094.75 vs. 0.27\u2009\u00b1\u20091.24, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), were also noted. In the trial group, one patient experienced mild eczema and one suffered low blood pressure, which could not be conclusively attributed to supplementation. Compared to the placebo group, the trial group showed a marked increase in <jats:italic>Enterococcus faecium<\/jats:italic> and a decrease in <jats:italic>Klebsiella.<\/jats:italic><\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study is the first to report that probiotics plus earthworm protein can remarkably improve the motor and some non-motor symptoms of PD without serious adverse effects. However, further clinical trials and exploration of the underlying mechanisms are required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p>Clinical trial registry <jats:uri>http:\/\/www.chictr.org.cn\/<\/jats:uri>, Identification No: ChiCTR2000035122.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1371791","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T04:41:36Z","timestamp":1725597696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of BF839\u2009+\u2009earthworm protein supplement on motor and some non-motor symptoms of Parkinson\u2019s disease: a randomized clinical trial"],"prefix":"10.3389","volume":"15","author":[{"given":"Ting","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.brainres.2018.01.010","article-title":"Parkinson\u2019s disease from the gut","volume":"1693","author":"Liddle","year":"2018","journal-title":"Brain Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e0142164","DOI":"10.1371\/journal.pone.0142164","article-title":"Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson\u2019s disease","volume":"10","author":"Hasegawa","year":"2015","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/brainsci10040206","article-title":"Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson\u2019s disease","volume":"10","author":"Hsieh","year":"2020","journal-title":"Brain Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41531-022-00327-6","article-title":"Probiotics synergized with conventional regimen in managing Parkinson's disease","volume":"8","author":"Sun","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0244680","DOI":"10.1371\/journal.pone.0244680","article-title":"Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson\u2019s disease: a randomised controlled trial","volume":"15","author":"Ibrahim","year":"2020","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jfda.2018.12.011","article-title":"Next generation probiotics in disease amelioration","volume":"27","author":"Chang","year":"2019","journal-title":"J Food Drug Anal"},{"key":"ref8","first-page":"216","article-title":"Isolation and identification of a nontoxic Bacteroides fragilis","volume":"13","author":"Zhang","year":"1991","journal-title":"Ningxia Med J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.13200\/j.cjb.1995.02.63.zhangjj.006","article-title":"Study on clinical application of Bacteroides fragilis (BF839)","volume":"8","author":"Zhang","year":"1995","journal-title":"Chin J Biol"},{"key":"ref10","first-page":"3828","article-title":"Treatment of psoriasis vulgaris using Bacteroides fragilis BF839: a single-arm, open preliminary clinical study","volume-title":"Sheng Wu Gong Cheng Xue Bao","author":"Lin","year":"2021"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.7507\/2096-0247.20210046","article-title":"The beneficial effect of Bacteroides fragilis (BF839) as a supplementary treatment in drug-resistant epilepsy: a pilot study","volume":"7","author":"Deng","year":"2021","journal-title":"J Epilepsy"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.7507\/2096-0247.202204008","article-title":"Assessing the effect of early use of bacteroides fragilis 839 in the treatment of \u201cpossible autoimmune-related epilepsy\u201d","volume":"8","author":"Lin","year":"2022","journal-title":"J Epilepsy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3760\/cma.j.cn115354-20211220-00835","article-title":"Bacteroides fragilis BF839 can improve learning, memory and social novelty of fragile X-mental retardation gene 1 knockout mice","volume":"21","author":"Lin","year":"2022","journal-title":"Chin J Neuromedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3969\/j.issn.1006-2084.2022.07.030","article-title":"Exploration of medication rule of Peiyuan Tongzhi method in treatment of Parkinson\u2019s disease based on auxiliary platform of traditional Chinese medicine inheritance","volume":"28","author":"Xu","year":"2022","journal-title":"Med Recapitulate"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.4014\/jmb.1507.07011","article-title":"Antimicrobial peptide, lumbricusin, ameliorates motor dysfunction and dopaminergic neurodegeneration in a mouse model of Parkinson\u2019s disease","volume":"25","author":"Kim","year":"2015","journal-title":"J Microbiol Biotechnol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson\u2019s disease: a double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.clnu.2018.05.018","article-title":"Clinical and metabolic response to probiotic administration in people with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Tamtaji","year":"2019","journal-title":"Clin Nutr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"937555","DOI":"10.3389\/fimmu.2022.937555","article-title":"Gut microbiota: a novel therapeutic target for Parkinson\u2019s disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/nyas.13660","article-title":"Finding a needle in a haystack: Bacteroides fragilis polysaccharide a as the archetypical symbiosis factor","volume":"1417","author":"Erturk-Hasdemir","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.cell.2013.11.024","article-title":"Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders","volume":"155","author":"Hsiao","year":"2013","journal-title":"Cell"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41392-020-00456-5","article-title":"Oral berberine improves brain dopa\/dopamine levels to ameliorate Parkinson\u2019s disease by regulating gut microbiota","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"728479","DOI":"10.3389\/fmicb.2021.728479","article-title":"Cross-sectional study on the gut microbiome of Parkinson\u2019s disease patients in Central China","volume":"12","author":"Mao","year":"2021","journal-title":"Front Microbiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota-gut-brain axis","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol Rev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/107602960000600109","article-title":"Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase","volume":"23","author":"Jin","year":"2000","journal-title":"Clin Hemorheol Microcirc"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00429-010-0246-0","article-title":"Cortical hypometabolism and hypoperfusion in Parkinson\u2019s disease is extensive: probably even at early disease stages","volume":"214","author":"Borghammer","year":"2010","journal-title":"Brain Struct Funct"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s0022-510x(03)00217-x","article-title":"Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson\u2019s disease","volume":"216","author":"Wong","year":"2003","journal-title":"J Neurol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.13412\/j.cnki.zyyl.2020.02.011","article-title":"Regulating mechanism of Dilongjiangya capsules on RAAS system in spontaneously hypertensive rats","author":"Zhao","year":"2020","journal-title":"Pharmacol Clin Chin Mater Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3969\/j.issn.1005-5304.2018.04.006","article-title":"Clinical study on Dilong Jiangya capsule in treatment of essential hypertension with subclinical atherosclerosis of hyperactivity of liver yang type","author":"Liu","year":"2018","journal-title":"Chin J Inf Trad Chin Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1371791\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T04:41:46Z","timestamp":1725597706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1371791\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":30,"alternative-id":["10.3389\/fneur.2024.1371791"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1371791","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fneur.2024.1371791.s001","asserted-by":"subject"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"article-number":"1371791"}}